Rob Baumgartner joined the MJ team in 1996 as a risk management consultant within our Risk Management + Commercial Insurance department. Over the years, he ascended to become a principal of the firm in 2008. Rob’s expertise lies in the construction, real estate development, and surety segments of our business.
Before venturing into the insurance industry, Rob kickstarted his career as an owner/operator of a family construction company. His background and extensive knowledge in this field have been the driving force behind his dedication to serving the unique needs of the construction, surety, and real estate industries.
Related Blogs
Health Care Industry Trends to Watch in 2026
Health care organizations enter 2026 facing numerous operational, financial and liability pressures, including labor shortages, inflation, supply chain volatility and the impact of U.S. ...
Read More
2025 Ended with Softest Market Conditions Since 2017 for all Account Sizes & Majority of Lines of Business, The Council’s P/C Market Survey Shows
The market appeared to move further into the soft part of the insurance market cycle in Q4 2025. Premiums across all account sizes rose ...
Read More
Miles for Miles Helps People With Intellectual and Developmental Disabilities Thrive
Miles Peck loves school as much for the chance to spend time with his friends as for the classroom experience. He is bracing his ...
Read More
EBSA Updates National Employee Benefit Plan Enforcement Projects for 2026
The Employee Benefits Security Administration (EBSA) announced updates to its national enforcement projects for fiscal year 2026. According to EBSA, these projects highlight areas ...
Read More
The Hard Market Is Shifting—Here’s What That Means for YOU
For years, organizations have been told the same thing at renewal: higher costs, fewer options, and little room to negotiate. Now, that message is ...
Read More
Employer Response to Pharma Shifts
Volatility in the pharmaceutical industry, including the expanding specialty drug pipeline, increased utilization of GLP-1 medications, and persistent supply chain disruptions, are contributing to rising costs ...
Read More